GSK
GSK
Market cap $77.4B

38.29 USD

+0.01

0.03%

At close Jul 14, 4:00 PM EDT

After hours

38.28

-0.01

0.03%

1 day

0.03%

5 days

0.84%

1 month

-5.43%

3 months

8.53%

6 months

19.36%

Year to date

12.78%

1 year

-0.98%

5 years

-24.74%

10 years

-29.33%

About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Employees: 68,629

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,315 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

66% more call options, than puts

Call options by funds: $243M | Put options by funds: $146M

40% more first-time investments, than exits

New positions opened: 91 | Existing positions closed: 65

22% more capital invested

Capital invested by funds: $11.6B [Q4 2024] → $14.2B (+$2.6B) [Q1 2025]

18% more repeat investments, than reductions

Existing positions increased: 322 | Existing positions reduced: 272

17% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 14 (+2) [Q1 2025]

0.62% more ownership

Funds ownership: 8.24% [Q4 2024] → 8.86% (+0.62%) [Q1 2025]

1% more funds holding

Funds holding: 832 [Q4 2024] → 837 (+5) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for GSK.

See Analyst Rankings

Financial journalist opinion

Based on 18 articles about GSK published over the past 30 days

Zacks Investment Research

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

GSK seeks FDA nod for expanded use of RSV vaccine in adults

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the age of 50 at a higher risk of the disease.

GSK seeks FDA nod for expanded use of RSV vaccine in adults

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

PHILADELPHIA--(BUSINESS WIRE)--GSK begins shipping influenza vaccine doses for the 2025-26 flu season.

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

Zacks Investment Research

GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK's Specialty Medicines Unit on a Strong Footing: Here's Why

GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025

GSK specialty medicines grew YoY in Q1 2025. In fact, it's now their main profit engine, offsetting the weakness in their vaccine segment. Similarly, the company's oncology, HIV, and respiratory biologics, plus the upcoming Blenrep FDA decision, could translate into additional near-term revenue catalysts. In my view, GSK's valuation multiples remain attractive and well below those of its peers—which is surprising, given its potential to generate over $40 billion in specialty medicines revenue by 2031.

GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025

Zacks Investment Research

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Proactive Investors

GSK counts on Blenrep rebound to drive £40bn sales goal

GSK PLC's (LSE:GSK, NYSE:GSK) long-term growth ambitions hinge in part on Blenrep, its treatment for multiple myeloma, a type of blood cancer. With the company aiming for more than £40 billion in annual sales by 2031, investors are watching closely how this high-margin medicine performs in the clinic and in the market.

GSK counts on Blenrep rebound to drive £40bn sales goal

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

US Senator investigates GSK for pulling children's asthma inhaler

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

US Senator investigates GSK for pulling children's asthma inhaler

Bharat, GSK to halve price of malaria vaccine by 2028

Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday.

Bharat, GSK to halve price of malaria vaccine by 2028

See News Rankings

Charts implemented using Lightweight Charts™